Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Executive Summary
Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)
You may also be interested in...
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.